Fast small molecule similarity searching with multiple alignment profiles of molecules represented in one-dimension

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6980-6990

  Wang, Norman ^a   DeLisle, Robert K ^a   Diller, David J ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; POTASSIUM CHANNEL; PROTEIN SERINE THREONINE KINASE; SERINE PROTEINASE;

ARTICLE; BIOINFORMATICS; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MOLECULAR SIZE; PROTEIN MOTIF; SEQUENCE ALIGNMENT;

ALGORITHMS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SRC-FAMILY KINASES;

EID: 27444432345     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050563r     Document Type: Article

References (50)

1. Martin, Y. C.; Kofron, J. L.; Traphagen, L. M. Do structurally similar molecules have similar biological activity? J. Med. Chem. 2002, 45, 4350-4358.
2. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 2002, 42, 1273-1280.
3. Makara, G. M. Measuring molecular similarity and diversity: total pharmacophore diversity. J. Med. Chem. 2001, 44, 3563-3571.
4. Mason, J. S.; Good, A. C.; Martin, E. J. 3-D pharmacophores in drug discovery. Curr. Pharm. Des. 2001, 7, 567-597.
5. McGregor, M. J.; Muskal, S. M. Pharmacophore fingerprinting. 1. Application to QSAR and focused library design. J. Chem. Inf. Comput. Sci. 1999, 39, 569-574.
6. McGregor, M. J.; Muskal, S. M. Pharmacophore fingerprinting. 2. Application to primary library design. J. Chem. Inf. Comput. Sci. 2000, 40, 117-125.
7. Rarey, M.; Stahl, M. Similarity searching in large combinatorial chemistry spaces. J. Comput. Aided Mol. Des. 2001, 15, 497-520.
8. Lemmen, C.; Lengauer, T.; Klebe, G. FLEXS: a method for fast flexible ligand superposition. J. Med. Chem. 1998, 41, 4502-4520.
9. Lemmen, C.; Lengauer, T. Computational methods for the structural alignment of molecules. J. Comput. Aided Mol. Des. 2000, 14, 215-232.
10. Barrett, A. J.; Rawlings, N. D. Families and clans of serine peptidases. Arch. Biochem. Biophys. 1995, 318, 247-250.
11. Fischer, D.; Wolfson, H.; Lin, S. L.; Nussinov, R. Three-dimensional, sequence order-independent structural comparison of a serine protease against the crystallographic database reveals active site similarities: potential implications to evolution and to protein folding. Protein Sci. 1994, 3, 769-778.
12. Krem, M. M.; Di Cera, E. Molecular markers of serine protease evolution. EMBO J. 2001, 20, 3036-3045.
13. Rawlings, N. D.; Barrett, A. J. Families of serine peptidases. Methods Enzymol. 1994, 244, 19-61.
14. Guner, O. F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top. Med. Chem. 2002, 2, 1321-1332.
15. Dixon, S. L.; Merz, K. M., Jr. One-dimensional molecular representations and similarity calculations: methodology and validation. J. Med. Chem. 2001, 44, 3795-3809.
16. Borg, I.; Groenen, P. Modern Multidimensional Scaling: Theory and Applications; Springer: New York, 1997.
17. Mohammad, S.; Zhou, Z.; Gong, Q.; January, C. T. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. 1997, 273, 2534-2538.
18. Kongsamut, S.; Kang, J.; Chen, X.; Roehr, J.; Rampe, D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 2002, 450, 37-41.
19. Fogel, L. J.; Owens, A. J.; Walsh, M. J. Artificial intelligence through simulated evolution; John Wiley and Sons: New York, 1966.
20. Holland, J. H. Adaptation is natural and artificial systems; Univesity of Michigan Press: Ann Arbor, 1975.
21. Baeck, T.; Fogel, D. B.; Michalewicz, Z.; Back, T.; Fogel, D. R. R. Evolutionary Computation 1: Basic Algorithms and Operators; Institute of Physics: Bristol, UK, 2000.
22. Baeck, T.; Fogel, D. B.; Michalewicz, Z. Evolutionary Computation 2: Advanced Algorithms and Operators; Institute of Physics: Bristol, UK, 2000.
23. Schwartz, R. M.; Dayhoff, M. O. Matrices for detecting distant relationships. Atlas of Protein Sequence and Structure; National Biomedical Research Foundation. Washington, D.C., 1978.
24. Henikoff, S.; Henikoff, J. G. Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10915-10919.
25. Gonnet, G. H.; Cohen, M. A.; Benner, S. A. Exhaustive matching of the entire protein sequence database. Science 1992, 256, 1443-1445.
26. Jones, D. T.; Taylor, W. R.; Thornton, J. M. The rapid generation of mutation data matrices from protein sequences. Comput. Appl. Biosci. 1992, 8, 275-282.
27. MDDR MDL Drug Data Report; MDL: San Leandro, CA.
28. Press: W. H.; Flannery, B. P.; Teukolsky, S. A.; Vetterling, W. T. Numerical recipes in C: The art of scientific computing, 2nd ed.; Cambridge University Press: New York, 1993; 994.
29. Frame, M. C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 2002, 1602, 114-130.
30. De Ponti, F.; Poluzzi, E.; Cavalli, A.; Recanatini, M.; Montanaro, N. Safety of nonantiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety 2002, 25, 263-286.
31. Roy, M.; Dumaine, R.; Brown, A. M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996, 94, 817-823.
32. Wang, Y. D.; Miller, K.; Boschelli, D. H.; Ye, F.; Wu, B. et al. Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett. 2000, 10, 2477-2480.
33. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Showalter, H. D. H. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
34. Traxler, P.; Green, J.; Mett, H.; Sequin, U.; P., F. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J. Med. Chem. 1999, 42, 1018-1026.
35. Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N. et al. Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
36. Klutchko, S. R.; Hamby, J. M.; Boschelli, D. H.; Wu, Z.; Kraker, A. J. et al. 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity. J. Med. Chem. 1998, 41, 3276-3292.
37. Hamby, J. M.; Connolly, C. J.; Schroeder, M. C.; Winters, R. T.; Showalter, H. D. et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 1997, 40, 2296-2303.
38. Boschelli, D. H.; Wang, D. Y.; Ye, F.; Yamashita, A.; Zhang, N. et al. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3- quinolinecarbonitriles. Bioorg. Med. Chem. Lett. 2002, 12, 2011-2014.
39. Boschelli, D. H.; Wu, Z.; Klutchko, S. R.; Showalter, H. D.; Hamby, J. M. et al. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J. Med. Chem. 1998, 41, 4365-4377.
40. Thompson, A. M.; Connolly, C. J.; Hamby, J. M.; Boushelle, S.; Hartl, B. G. et al. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase. J. Med. Chem. 2000, 43, 4200-4211.
41. Missbach, M.; Altmann, E.; Widler, L.; Susa, M.; Buchdunger, E. et al. Substituted 5,7-diphenylpyrrolo[2,3-d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett. 2000, 10, 945-949.
42. Connolly, C. J. C.; Hamby, J. M.; Schroeder, M. C.; Barvian, M.; Lu, G. H. et al. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 2415-2420.
43. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
44. Catalyst; 4.8 ed.; Accelrys, Inc.: San Diego, CA.
45. Cerius2; 4.9 ed.; Accelrys Inc.; San Diego, CA.
46. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 307, 427-434.
47. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A. et al. Crystal structure of Hck in complex with a Src family selective tyrosine kinase inhibitor. Mol. Cell 1999, 3, 639-648.
48. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
49. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
50. de Laszlo, S. E.; Hacker, C.; Li, B.; Kim, D.; MacCoss, M. et al. Potent, orally absorbed glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 641-646.